Completed PHASE3 INTERVENTIONAL 2-arm NCT01813630

A Clinical Study to Assess the Efficacy and Safety of DA-3002

Phase III Clinical Trial for Assessment of Efficacy and Safety of DA-3002 (Recombinant Human Growth Hormone) in Patients With Turner's Syndrome

Sponsor: Dong-A ST Co., Ltd.

Conditions Turner's Syndrome

Interventions DA-3002 Genotropin®

Updated 8 times since 2017 Last updated: Jul 24, 2018 Started: Feb 28, 2013 Primary completion: May 31, 2018 Completion: May 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Turner's Syndrome, this trial is completed. The trial is conducted by Dong-A ST Co., Ltd. and has accumulated 8 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Aug 2018 — Jan 2021 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed

▶ Show 3 earlier versions

Jun 2018 — Aug 2018 [monthly]

Active Not Recruiting PHASE3
Oct 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE3

Status: Unknown Status → Active Not Recruiting
Jan 2017 — Oct 2017 [monthly]

Unknown Status PHASE3

First recorded

Feb 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dong-A ST Co., Ltd.

Data source: Dong-A ST Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea